Business UpdateApr 21, 2026, 05:31 PM
RVMD Unveils New Catalytic RAS(ON) Inhibitors in Preclinical Data
AI Summary
Revolution Medicines announced promising preclinical data for a new class of mutant-targeted catalytic RAS(ON) inhibitors. These inhibitors, exemplified by RM-055, are designed to convert active mutant RAS to an inactive state, mimicking physiological regulation. Preclinical studies showed RM-055 drove deep and durable tumor regressions across various KRAS G12 mutant xenograft models, notably overcoming resistance to existing RAS inhibitors. This novel mechanism aims to address tumor resistance and extend the durability of current RAS-targeted therapies.
Key Highlights
- Revolution Medicines announced preclinical data for new mutant-targeted catalytic RAS(ON) inhibitors.
- RM-055, an oral compound, showed robust and durable antitumor activity in KRAS G12 mutant xenograft models.
- RM-055 overcame resistance to prior RAS inhibitor treatments in preclinical models.
- The new class of inhibitors stimulates GTPase activity of mutant RAS variants, converting RAS(ON) to RAS(OFF).
- Data presented at the AACR Annual Meeting on April 21, 2026 (Abstract #6782).